Regulation of Cellular Processes by Interleukin‐16 in Homeostasis and Cancer
- 25 October 2013
- journal article
- review article
- Published by Wiley in Journal of Cellular Physiology
- Vol. 229 (2), 139-147
- https://doi.org/10.1002/jcp.24441
Abstract
Interleukin‐16 (IL‐16) is generated as a precursor molecule that is cleaved by caspase‐3 to produce a pro‐IL‐16 molecule that functions as a regulator of T cell growth, and a secreted peptide that functions as a CD4 and/or CD9 ligand for induction of cell motility and activation. IL‐16 has been predominantly studied as a contributing factor in the orchestration of an immune response; however, more recently IL‐16 bioactivity has been closely associated with the progression of a number of different cancers. While the association between IL‐16 plasma levels and tumor progression has been reported for many types of cancer, the mechanism for IL‐16 involvement has been partially elucidated for three of the cancer types, cutaneous T cell lymphoma (CTCL), multiple myeloma (MM), and breast cancer. The mechanism for promoting cell growth is different in each of these cancers and involves a sequence mutation in the pro‐molecule facilitating decreased p27KIP1 levels in CTCL; over expression of the secreted IL‐16 molecule to induce proliferation in CTCL T cells, and plasma cells in MM; and increased secreted IL‐16 acting to recruit CD4+ pro‐tumor macrophages in breast cancer. This article will review the cellular process for generating IL‐16, the biological activities for both the pro‐ and secreted forms of the protein, and then the mechanism by which these forms contribute to cancer progression. As a soluble cytokine the ability to reduce or eliminate IL‐16 synthesis through siRNA approaches or bioactivity through the use of neutralizing antibody treatment may represent a novel therapeutic approach. J. Cell. Physiol. 229: 139–147, 2014.Keywords
This publication has 87 references indexed in Scilit:
- miR‐29a inhibition normalizes HuR over‐expression and aberrant AU‐rich mRNA stability in invasive cancerThe Journal of Pathology, 2013
- Loss of nuclear pro–IL-16 facilitates cell cycle progression in human cutaneous T cell lymphomaJCI Insight, 2011
- Neutralization of Interleukin-16 Protects Nonobese Diabetic Mice From Autoimmune Type 1 Diabetes by a CCL4-Dependent MechanismDiabetes, 2010
- IL‐16 polymorphism and risk of renal cell carcinoma: Association in a Chinese populationInternational Journal of Urology, 2010
- Tissue expression of IL16 in prostate cancer and its association with recurrence after radical prostatectomyThe Prostate, 2010
- Serum levels of Interleukin‐16 in a multiple myeloma patient with cutaneous involvementInternational Journal of Dermatology, 2010
- IL-2– and IL-15–induced activation of the rapamycin-sensitive mTORC1 pathway in malignant CD4+ T lymphocytesBlood, 2008
- Interleukin-16 and peptide derivatives as immunomodulatory therapy in allergic lung diseaseExpert Opinion on Biological Therapy, 2004
- Inhibitory effect of interleukin‐16 on interleukin‐2 production by CD4+ T cellsImmunology, 1999
- Interleukin 16 and its function as a CD4 ligandImmunology Today, 1996